Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 16. xxxxxxxxx 2007 xxxx generálním xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx¹⁾, xxxxxxxx schválení nového xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx.

Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2008 x xxxxx xxxx vstoupila x xxxxxxxx i xxx Xxxxxx republiku. Xxxx xxxxxx Xxxxxxx X x xxxxxxxx přestává xxxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx xx xxxxx xxx xxx 2007, xxxxxxxxx xxx č. 59/2007 Xx. x. x.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx se vyhlašují xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):

x. Exogenní * XXX, xxxxxxxxxx:

1-androstendiol (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (19-norandrostendiol); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; klostebol; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolom; methandriol; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); methyl-1-testosteron (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxx; nandrolon; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), testosteron x následující xxxxxxxxxx x isomery:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

androst-4-en-3α,17α-diol 3α-hydroxy-5αandrostan-17-on

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

androst-5-en-3α,17β-diol

V xxxxxxxxx, xxx xxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx steroid xxxxxxxxx, xxxx xx mít xx xx, xx Xxxxxx xxxxxxxx xxxx Xxxxxxxxx xxxxx x xxxx hlášen xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx nebo xxxxxxxxxxx x/xxxx když xx jakýkoli xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxx xx rozmezí xxxxxx, xxxxx se xxxxxxxx xxxxxxxxx x xxxx xxx, xx xxxxxxxxxx normální xxxxxxxxx xxxxxxxx. Xxxxxx xx xxx xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx v xxxxxxx případě, xxxxx Xxxxxxxxx xxxxxxx, xx xx koncentrace Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx xxxxxxxxx poměr xx Xxxxxx Sportovce xxxxxxxx fyziologickým xxxx xxxxxxxxxxxx stavem.

Bude xx xxx xx xx, že Vzorek Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx xx xxxxx xxxxxxxxx x xxx xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, xx xx Zakázaná xxxxx xxxxxxxxxx xxxxxx. X xxxxxxx xxxxxxx není xxxxx xxxxxxxx xxxxx xxxxxxx.

Když se xxxxxxx xxxxxxxx analýzy xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx x xxxx x xxxxx spolehlivá xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx exogenní xxxxx Xxxxxxxx látky, ale xxxxxxxx známky použití Xxxxxxxx xxxxx, xxxx xxxx. xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxx xxxx xxxxxxxxx nahlásila xxxxx X/X xxxxx xxx xxxxx (4) ku xxxxx (1) a xxxxx spolehlivá xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx exogenní xxxxx xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx výsledků xxxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxxxxx testů.

Xx-xx vyžadováno takové xxxxx xxxxxxx, xxx xxxxxxxx bude laboratoří xxxxxx xxxx neobvyklý x xx xxxx xxxxxxxxx. Xxxxx xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx analytické xxxxxx (xxxx. IRMS) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxxxx xxxxxxxx xxxxx xxxxxxx, a xxxx se mít xx xx, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx. Xxxxx xxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. XXXX) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx xxx, xx xxxx xxxxxxxxxx Antidopingovou xxxxxxxxxx x xxxxxxxxxxxxx 3 xxxxxxxx třikrát xxxxxxxx xxx předchozího xxxxxxxx. Xxxxxxxx, který xxxxxxxxxx xxxx xxxxxxxxxxxxxx xxxxxx, xxxx hlášen xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx fyziologicky xxxxxxxx, xxxx xx xxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx.

V xxxxxxxx vzácných xxxxxxxxxxxxxx xxxxxxxxx xxxx být x xxxx trvale xxxxxxx boldenon xxxxxxxxxxx xxxxxx xx velice xxxxxx koncentracích (ng/ml). Xxxxx xxxxxxxxx takový xxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxx provedeno další xxxxxxx xxxxxxxxxx následného xxxxx (xxxxxxxxxx xxxxx).

Xxxxx xxxxxxxxx xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, xxxx xx xx xxxxxxxxx xx xxxxxxx x xxxxxxxxxxx xxxxx xxxxxxxxxx xxxxxx Xxxxxxxx xxxxx. V xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx další xxxxxxx.

X xxxxxxx, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx při dalších xxxxxxxxx, xxxx xx xxx xx to, xx Vzorek Sportovce xxxxxxxx Xxxxxxxxx xxxxx.

2. Xxxxxxx anabolické xxxxx, zahrnující:

Klenbuterol, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

X2. XXXXXXX X XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (XXX);

2. Xxxxxxx xxxxxx (xXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxxx (xxxx. XXX-1), mechanické xxxxxxx xxxxxxx (MGF);

3. Xxxxxxxxxxxxx (xxxx. LH, xXX), xxxxxxxx xxx x xxxx;

4. Xxxxxxxx;

5. Kortikotropiny

x další xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

Xxxxx Xxxxxxxxx xxxxxx xxxxxxxx, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxx, bude xx xxx za xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx (xxx je uvedeno xxxx) v xxxxxxxxx, xxx koncentrace Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Vzorku Xxxxxxxxx xxxxxxx xxxxxxxx hodnoty xxxxxxxx xxxxxxxx x xxxx xxx, že xxxxxxxxxxxx xxxxxxxx endogenní xxxxxxxx.

Pokud xxxxxxxxx xxxxxxxxx, xx xxxxx xxxxxxxxxx analytické metody, xx Zakázaná xxxxx xx xxxxxxxxxx xxxxxx, xxxx xx mít xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx x bude xxxxxxx Pozitivní xxxxxxxxxxx xxxxx.

X3. XXXX-2 AGONISTÉ

Všichni xxxx-2 agonisté xxxxxx xxxxxx X- x X-xxxxxxx xxxx zakázáni.

Xxxxxxxx xxxx formoterol, xxxxxxxxxx, salmeterol x xxxxxxxxxx, xxx které xx xxx inhalaci xxxxx udělení zkrácené xxxxxxxxxxxx xxxxxxx.

X xxxx byla xxxxxxx xxxxxxxx forma xxxxxxxxxxxx xxxxxxx, bude xxxxx xxxxxxxxxxx (xxxxx plus xxxxxxxxxx) xxxxx xxx 1000 xxxxxxxxx x 1 xxxxxxxxx moči xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxxxx, že xxxxxxxxxx výsledek xxx xxxxxxxx terapeutickým xxxxxxxx xxxxxxxxxxx x xxxxxxxx.

X4. XXXXXXXXXXX X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx skupiny xxxx xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, zahrnující:

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx ně.

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX

Xxxxxxxxx látky xxxx xxxxxxxx. Zahrnují:

Xxxxxxxxx*, xxxxxxxxxxxxxx, probenecid, xxxxxxxxxx xxxx-xxxxxxxxx (např. xxxxxxxxxx, dutasterid), plasmaexpandery (xxxx. albumin, dextran, xxxxxxxxxxxxxxxxx) a xxxxx xxxxx x podobnými xxxxxxxxxxxx účinky.

Xxxxxxxxx xxxxxxxx:

Acetazolamid, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, chlorothiazid), xxxxxxxxxx x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx xxxxxx, xxxxx xxx Xxxxxxxxx xxxxxxxx xxxxxxxxx ve xxxxxxx x prahovou xxxx podprahovou xxxxxxxx xxxx Xxxxxxxx xxxxx (xxxxx).

X1. ZVYŠOVÁNÍ XXXXXXX XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

X3. XXXXXX XXXXXX

Neterapeutické xxxxxxx buněk, xxxx, xxxxxxxx xxxxxxxx, xxxx xxxxxxxxxx exprese xxxx, xxxxx mají xxxxxxxxx xxxxxx sportovní xxxxx, xx xxxxxxxx.

X6. XXXXXXXXXXX

Všechna xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx (X- x X-) xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx v případě xxxxxx xxxxxxxx xxxxx x stimulancií xxxxxxxxxx xx Monitorovacího programu xxx xxx 2008.

Xxxxxxxxxxx zahrnují:

Adrafinil, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, amfetamin, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, methylfenidát, xxxxxxxx, modafinil, niketamid, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, oxilofrin, parahydroxyamfetamin, xxxxxxx, xxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx x xxxxx xxxxxx xxxx xxxxxxxxxx za specifickou xxxxx pouze, xxxxx Xxxxxxxxx xxxxxxx, xx xxxx xxxxxxxxx dostupnost x xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx antidopingových xxxxxxxx, xxxx je u xxx menší xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx jako xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx zakázaná:

Buprenorfin, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

S8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, xxxxxxxxx) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx. Xxxxxx užití vyžaduje xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx xxxxxxxx xxxxxxxx (xxxxxxxxxxxx, do xxxxx xxxxxx, xx xxxxx xxxxxx, xxxxxxxxxx, xx xxxx) a xxxxxxxxx xxxxxxxx vyžadují xxxxxxxxx xxxxxxxxxxxxx výjimku x xxxxxxxx níže xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx potíže xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), ušní, xxxxx, oční, potíže xxxxx xxxxxxx xxxxxx, xxxxxxxx xxx x xxxxx nejsou xxxxxxxx x xxxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxx výjimky.

X1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx pravidla (xxxxxxxxxxxxx xxxxxxx) je xxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (XXX) (0.10 x/x)

∙ Xxxxxx (XXX) (0.10 x/x)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Lukostřelba (XXXX, XXX) (0.10 g/l)

∙ Xxxxxxx pětiboj (XXXX) xxx xxx xxxxxxxxxx xx xxxxxxxx (0.10 x/x)

∙ Motocyklový xxxxx (XXX) (0.10 g/l)

∙ Xxxxx motorismus (XXX) (0.30 x/x)

∙ Xxxxxxx (XXX) (0.10 x/x)

X2. BETA-BLOKÁTORY

Pokud xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány xxxxx Xxx soutěži x následujících sportech.

∙ Xxxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Bridž (XXX)

∙ Curling (XXX)

∙ Gymnastika (XXX)

∙ Jachting (XXXX) - "xxxxx xxxx" - xxx xxxxxxxxxxx

∙ Kuželky (XXX)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Mimo soutěž)

∙ Lyžování (XXX) - skoky xx xxxxxx a xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx, x xxxxxxxxx X-xxxxx x "xxx xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - jen xxxxxxxxxx se střelbou

∙ Xxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX, XXX "xxxxx")

∙ Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (XXX)

∙ Xxxxx (FILA)

Xxxx-xxxxxxxxx zahrnují následující xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, metipranolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx

"Specifické xxxxx"* xxxx xxxxxxxxxxx níže:

∙ Xxxxxxx Xxxx-2 xxxxxxxx x xxxxxxxx, xxxxx salbutamolu (volného xxxx xxxxxxxxxxx) xxx xxxxxxxx větším xxx 1000 ng/ml xxxx x clenbuterolu (xxxxxxx xx skupině X 1.2 Ostatní anabolické xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, kropropamid, xxxxxxxxxx, xxxxxxx, etamivan, xxxxxxxxxxx, xxxxxxxxxxxxx, haptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, niketamid, norfenefrin, xxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxx, selegilin, sibutramin, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx neuvedená xxxxxxxx x xxxxxx X6, xxx xxxxx Xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxx popsané x xxxxxx X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Glukokortikosteroidy;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx xxx vyjmenovány xxxxxxxxxx látky, xxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx antidopingových xxxxxxxx, xxxxxxx xxxx xxxxxxxxx xxxxxxxx v xxxxxxx xxxxxxxxx xxxxxxxxxxx, nebo x xxxxx xx xxxxx pravděpodobnost, xx xxxxx xxxxxxx xxxxxxxx xxxx dopingová xxxxxxx." Xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx xxxx xxxxxxxx xxxxxxx xxxxxx za předpokladu, xx "...Xxxxxxxxx může xxxxx xxxxxxxx, xx Xxxxxxx xxxxxxxxxx látky xxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu...".

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. xxxxx xxxxxxxxx xxxx 31.1.2008.

Xxxxxx předpis x. 2/2008 Xx. m. x. byl zrušen xxxxxxx předpisem č. 8/2009 Sb. m. s. x xxxxxxxxx od 7.2.2009.

Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud se xxxx netýká xxxxxxxxx xxxxx shora uvedeného xxxxxxxx xxxxxxxx.